Author:
Fallowfield Lesley,McGurk Rhona,Dixon Michael
Reference30 articles.
1. Scottish Cancer Trials Breast Group and ICRF Breast Unit GsH. Adjuvant ovarian ablation versus CMF chemotherapy in premenopausal women with pathological stage II breast carcinoma: the Scottish trial. Lancet 1993, 341 (8856), 1293–98
2. Roche H, Kerbrat P, Bonneterre J, Fargeot P, Fumoleau P, Monnier A, et al. Complete Hormonal, Blockade Versus Chemotherapy in Premenopausal Early-Stage Breast Cancer Patients (Pts) with Positive Hormone-Receptor (HR+) and 1–3 Node-Positive (N+) Tumor: results of the FASG 06 Trial. In Proceedings of the American Society of Clinical Oncology, 2000, p. 279 (abstract)
3. Ovarian ablation in the adjuvant treatment of premenopausal and perimenopausal breast cancer;Sainsbury;Brit. J. Surg.,2003
4. Boccardo F, Rubagotti A, Amoroso D, Mesiti M, Romeo D, Sismondi P, et al. Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: results of the Italian Breast Cancer Adjuvant Study Group 02 randomized trial. J Clin Oncol 2000, 18(14), 2718–27. Available from: boccardo@hp380.ist.unige.it
5. Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study;Jonat;J. Clin. Oncol.,2002
Cited by
36 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献